Trial Profile
A Study to Evaluate the Predictive Role of Tumour Markers in Patients with Advanced-stage Non Small Cell Lung Cancer (NSCLC) Treated with tyrosinkinase inhibitors (TKIs), bevacizumab and pemetrexed:TULUNG registry
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Nov 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Alectinib (Primary) ; Atezolizumab (Primary) ; Bevacizumab (Primary) ; Ceritinib (Primary) ; Crizotinib (Primary) ; Dabrafenib (Primary) ; Durvalumab (Primary) ; Erlotinib (Primary) ; Gefitinib (Primary) ; Lorlatinib (Primary) ; Nintedanib (Primary) ; Nivolumab (Primary) ; Osimertinib (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Trametinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Pharmacodynamics; Therapeutic Use
Most Recent Events
- 01 Nov 2021 Results assessing the prognostic and predictive value of EGFRExon-20 insertions in Czech patients with advanced non-small cell lung cancer, published in the Anticancer Research.
- 01 Apr 2021 Results (N=105) of an analysis assessing the prognostic role for CYFRA 21-1 in patients with advanced-stage NSCLC treated with Bevacizumab plus chemotherapy, published in the Anticancer Research
- 10 Sep 2019 Results from 1st line treatment patients (n=470) presented at the 20th World Conference on Lung Cancer